Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy

Immunosuppressive therapy increases the risk of pneumococcal disease. This risk can be mitigated by pneumococcal vaccination. The objective of this study was to investigate the immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13), followed by the 23-valent pneumococcal polysacchari...

Descrición completa

Detalles Bibliográficos
Main Authors: Hannah M. Garcia Garrido, Albert Vollaard, Geert R. D’Haens, Phyllis I. Spuls, Frederike J. Bemelman, Michael W. Tanck, Godelieve J. de Bree, Bob Meek, Martin P. Grobusch, Abraham Goorhuis
Formato: Artigo
Idioma:English
Publicado: MDPI AG 2022-05-01
Series:Vaccines
Subjects:
pneumococcal vaccination
immunocompromised host
transplant recipient
autoimmune disease
vaccine immunogenicity
Acceso en liña:https://www.mdpi.com/2076-393X/10/5/795

Internet

https://www.mdpi.com/2076-393X/10/5/795

Títulos similares